NASDAQ:SNPX

Synaptogenix Stock Forecast, Price & News

$7.60

-0.20 (-2.56 %)

(As of 07/30/2021 12:00 AM ET)

Add

Compare

Today's Range

$7.32

▼

$8.53

50-Day Range N/A

52-Week Range

$2.60

▼

$14.40

Volume441,035 shs

Average Volume749,556 shs

Market Capitalization$45.90 million

P/E RatioN/A

Dividend YieldN/A

BetaN/A

30 days | 90 days | 365 days | Advanced Chart

Receive SNPX News and Ratings via Email

Sign-up to receive the latest news and ratings for Synaptogenix and its competitors with MarketBeat's FREE daily newsletter.

About Synaptogenix

Synaptogenix, Inc. operates as a biopharmaceutical company. It focuses on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and niemann-pick type C disease. It has licensing agreements with Stanford University; Icahn School of Medicine; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is based in New York, New York.

Synaptogenix (NASDAQ:SNPX) Stock Price Up 4.7%
July 29, 2021 | americanbankingnews.com

Synaptogenix Announces Conference Call to Discuss AAIC Abstract Findings
July 21, 2021 | finance.yahoo.com

Synaptogenix to Present Data at Alzheimer's Association International Conference 2021 Highlighting Bryostatin Restores Cognitive Function Above Baseline
July 14, 2021 | finance.yahoo.com

Synaptogenix (NASDAQ:SNPX) Shares Down 13.2%
July 8, 2021 | americanbankingnews.com

Synaptogenix Announces Regenerative Patent Award to Treat Alzheimer's Disease
July 7, 2021 | finance.yahoo.com

Synaptogenix Announces Live Appearance of its President and CSO on Streaming Financial News Network
June 24, 2021 | finance.yahoo.com

Synaptogenix, Inc: Invitation to the Benzinga Global Small Cap Conference
June 21, 2021 | finance.yahoo.com

Synaptogenix Announces Plan to Uplist on the Nasdaq Stock Market
June 21, 2021 | finance.yahoo.com

Is Synaptogenix (NASDAQ:SNPX) In A Good Position To Deliver On Growth Plans?
June 21, 2021 | finance.yahoo.com

Synaptogenix Announces Phase 2b NIH Sponsored Alzheimer's Disease Trial Update
June 21, 2021 | finance.yahoo.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SNPX
Previous Symbol
CUSIPN/A
CIK1571934
Webwww.synaptogen.com
Phone973 242 0005
Employees4
Year FoundedN/A

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares6,040,000
Market Cap$45.90 million
Next Earnings DateN/A
OptionableNot Optionable

MarketRank^™

Overall MarketRank^™

0.33 out of 5 stars

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Synaptogenix.

0.0 Community Rank

Outperform Votes
Synaptogenix has received 0 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Synaptogenix has received 0 “underperform” votes. (Add your “underperform” vote.)

MarketBeat's community ratings are surveys of what our community members think about Synaptogenix and other stocks. Vote “Outperform” if you believe SNPX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe SNPX will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Synaptogenix does not currently pay a dividend.
Dividend Growth
Synaptogenix does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Synaptogenix insiders have bought more of their company's stock than they have sold. Specifically, they have bought $82,600.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 1.76% of the stock of Synaptogenix is held by insiders.

0.0 Earnings and Valuation

See Top Rated MarketRank™ Stocks Here

Synaptogenix (NASDAQ:SNPX) Frequently Asked Questions

What stocks does MarketBeat like better than Synaptogenix?

Wall Street analysts have given Synaptogenix a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Synaptogenix wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Who are Synaptogenix's key executives?

Synaptogenix's management team includes the following people:

Dr. Alan J. Tuchman, CEO & Director (Age 74, Pay $184.38k)
Dr. Daniel L. Alkon, Pres, Chief Scientific Officer & Director (Age 79, Pay $300k)
Mr. Robert Weinstein, CFO, Sec. & Exec. VP (Age 61, Pay $494.64k)

Who are some of Synaptogenix's key competitors?

Some companies that are related to Synaptogenix include Zynerba Pharmaceuticals (ZYNE), Tricida (TCDA), Chemomab Therapeutics (CMMB), Decibel Therapeutics (DBTX), AVEO Pharmaceuticals (AVEO), MediciNova (MNOV), Seelos Therapeutics (SEEL), Adamis Pharmaceuticals (ADMP), Gemini Therapeutics (GMTX), Mereo BioPharma Group (MREO), Ardelyx (ARDX), Biofrontera (BFRA), Corbus Pharmaceuticals (CRBP), Aptinyx (APTX) and Milestone Pharmaceuticals (MIST).
View all of SNPX's competitors.

What is Synaptogenix's stock symbol?

Synaptogenix trades on the NASDAQ under the ticker symbol "SNPX."

How do I buy shares of Synaptogenix?

Shares of SNPX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Synaptogenix's stock price today?

One share of SNPX stock can currently be purchased for approximately $7.60.

How much money does Synaptogenix make?

Synaptogenix has a market capitalization of $45.90 million.

How many employees does Synaptogenix have?

Synaptogenix employs 4 workers across the globe.

What is Synaptogenix's official website?

The official website for Synaptogenix is www.synaptogen.com.

Where are Synaptogenix's headquarters?

Synaptogenix is headquartered at 1185 AVENUE OF THE AMERICAS 3RD FLOOR, NEW YORK NY, 10036.

How can I contact Synaptogenix?

Synaptogenix's mailing address is 1185 AVENUE OF THE AMERICAS 3RD FLOOR, NEW YORK NY, 10036. The company can be reached via phone at 973 242 0005 or via email at [email protected]

This page was last updated on 8/1/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Synaptogenix Stock Forecast, Price & News

About Synaptogenix

Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous

MarketRank™

Overall MarketRank™

0.0 Analyst's Opinion

Consensus Rating

0.0 Community Rank

Outperform Votes

Underperform Votes

0.0 Dividend Strength

Dividend Yield

Dividend Growth